‘Education regarding a womans skeletal health risks is important during the menopause transition.’
According to Dr. Michael McClung, a member of the NAMS board and Co-Lead of the Editorial Panel for the 2021 Osteoporosis Position Statement, NAMS reviewed knowledge on these therapies, in addition to on rising therapy modalities, when drafting its findings.
Highlights from the 2021 place assertion on osteoporosis administration embody roughly half of ladies aged 50 years will expertise a fracture associated to osteoporosis of their lifetimes.
Estrogen deficiency at menopause is the first reason behind bone loss that results in osteoporosis.
Even with optimum normal measures such pretty much as good diet and common bodily exercise, osteoporosis progresses with advancing age until it’s handled. Life-long administration is required as soon as the analysis has been made.
Hormone remedy is probably the most acceptable selection to forestall bone loss on the time of menopause for wholesome girls, significantly those that have menopause signs.
Bone mineral density measured whereas on therapy correlates with the affected person’s present danger of fracture, offering justification for using the T-score on the hip as an acceptable scientific goal guiding decisions of remedy.
Although anti-remodeling medication are chosen to deal with most sufferers with osteoporosis, a brand new paradigm of starting therapy with a bone-building agent adopted by an anti-remodeling agent is really helpful for ladies at very excessive danger of fractures.
This new place assertion on osteoporosis offers clinicians with a sensible information to assessing and managing bone well being in postmenopausal girls and emphasizes an individualized strategy with common follow-up and adjustment primarily based on altering scientific wants and affected person choice.